Indirubin-3-monoxime is a potent GSK-3β inhibitor, and weakly inhibits 5-Lipoxygenase, with IC₅₀s of 22 nM and 7.8-10 μM, respectively; Indirubin-3-monoxime also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B, with IC₅₀s of 100 and 180 nM.

Solid

Indirubin-3-monoxime inhibits GSK-3β by competing with ATP, with K_i of 0.85 μM, and K_m of 110 μM. Indirubin-3-monoxime also inhibits tau phosphorylation by GSK-3β, with an IC₅₀ value of around 100 nM. Indirubin-3-monoxime completely inhibits the phosphorylation of the AT100 epitope. Indirubin-3-monoxime inhibits vascular smooth muscle cell (VSMC) proliferation with IC₅₀ of ～2 μM. Indirubin-3-monoxime blunts migration of VSMC stimulated with the PDGF. Indirubin-3-monoxime interferes with the migratory response in VSMC, and also suppresses the production of pro-migratory LT in monocytes. Moreover, Indirubin-3-monoxime inhibits 5-lipoxygenase (5-LO) product synthesis in monocytes and neutrophils, with the same potency (IC₅₀=5.0±1.1 and 3.7±1.2 μM, respectively). Indirubin-3-monoxime is an inhibitor of 5-LO, with IC₅₀ of 7.8-10 μM in cell-free assay.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Indirubin-3-monoxime (0.1, 0.2 and 0.4 mg/kg, i.p) dose dependently reverses the cognitive impairment and combats the elevated oxidative stress markers in HFD fed mice. Indirubin-3-monoxime also dose dependently lowers the serum glucose, TGs, TC and insulin levels, and improves the β-cell functioning in HFD fed mice. Moreover, Indirubin-3-monoxime treatment significantly decreases HOMA-IR levels compared to HFD group. Indirubin-3-monoxime (0.4 mg/kg) significantly attenuates the increased EL in the HFD group.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature or refrigerated transportation.

• [1]. Leclerc S, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimers disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 2001 Jan 5;2  [Information]

  [2]. Sharma S, et al. Neuroprotective role of Indirubin-3-monoxime, a GSKβ inhibitor in high fat diet induced cognitive impairment in mice. Biochem Biophys Res Commun. 2014 Oct 3;452(4):1009-15.  [Information]

  [3]. Blazevic T, et al. Indirubin-3-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration. Cardiovasc Res. 2014 Mar 1;101(3):522-32.  [Information]

  [4]. Cao Z, et al. Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer [published online ahead of print, 2021 Oct 8]. J Med Chem. 2021;10.1021/acs.jmedchem.1c01311.  [Information]

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。